低危前列腺癌主动监测方案依从性:GAP3 全球队列结果
结果显示 PSA、Gleason 评分和阳性穿刺针数标准的依从率分别为 92%、97% 和 94%,年龄和 T 分期标准依从率均为 99%;重复穿刺的非依从率随监测时间延长而升高,且与穿刺频率无关。
要点
- PSA、Gleason 评分、阳性针数、年龄和 T 分期纳入标准的依从率分别为 92%、97%、94%、99% 和 99%。
- 年度活检方案在 1、4、7 年的非依从率分别为 8%、16%、34%。
- PRIAS 方案在 1、4、7 年的非依从率分别为 11%、30%、29%,与年度方案无差异。
核心结论
- 主动监测纳入标准总体依从性较好,但 PSA 和 Gleason 评分标准的依从存在差异,制定循证方案时应予考虑。
- 重复穿刺依从性随监测时间延长而下降,且与活检频率无关,强调监测开始时进行风险分层的重要性。
研究设计与样本
- 采用五点 Likert 量表评估各纳入标准的依从性;随访非依从定义为计划日期后 1 年仍未进行重复活检。
- 队列按年度活检方案和 PRIAS 方案合并,使用广义线性混合模型检验非依从性。
主要发现
- 血清 PSA 纳入标准依从率为 92%,Gleason 评分标准为 97%,阳性活检针数标准为 94%。
- 年龄和肿瘤 T 分期标准的依从率均为 99%。
- 年度活检方案在 1、4、7 年的非依从率分别为 8%、16%、34%;PRIAS 方案分别为 11%、30%、29%。
- 两种活检方案之间的非依从率无差异。
关键数值与推荐
- PSA 标准依从率 92%,Gleason 评分标准 97%,阳性活检针数标准 94%,年龄和 T 分期标准均为 99%。
- 年度活检方案非依从率:1 年 8%、4 年 16%、7 年 34%。
- PRIAS 方案非依从率:1 年 11%、4 年 30%、7 年 29%。
临床怎么用
- 启动主动监测时应重视风险分层,以应对随监测时间延长而下降的重复穿刺依从性。
- 优化主动监测方案时需考虑 PSA 和 Gleason 评分纳入标准的依从差异。
局限性
- 结果未考虑多参数磁共振成像(mpMRI)的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) enrolment criteria and follow-up schedules for low-risk prostate cancer vary between institutions. However, uncertainty remains about adherence to these protocols. OBJECTIVE: To determine adherence to institution-specific AS inclusion criteria and follow-up schedules within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively assessed the data of 15 101 patients from 25 established AS cohorts worldwide between 2014 and 2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Adherence to individual AS inclusion criteria was rated on a five-point Likert scale ranging from poor to excellent. Nonadherence to follow-up schedules was defined as absence of repeat biopsy 1 yr after the scheduled date. Cohorts were pooled into annual and Prostate Cancer Research International: Active Surveillance (PRIAS)-based biopsy schedules, and a generalised linear mixed model was constructed to test for nonadherence. RESULTS AND LIMITATIONS: Serum prostate-specific antigen (PSA) inclusion criteria were followed in 92%, Gleason score (GS) criteria were followed in 97%, and the number of positive biopsy cores was followed in 94% of men. Both age and tumour stage (T stage) criteria had 99% adherence overall. Pooled nonadherence rates increased over time-8%, 16%, and 34% for annual schedules and 11%, 30%, and 29% for PRIAS-based schedules at 1, 4, and 7 yr, respectively-and did not differ between biopsy schedules. A limitation is that our results do not consider the use of multiparametric magnetic resonance imaging. CONCLUSIONS: In on-going development of evidence-based AS protocols, variable adherence to PSA and GS inclusion criteria should be considered. Repeat biopsy adherence reduces with increased duration of surveillance, independent of biopsy frequency. This emphasises the importance of risk stratification at the commencement of AS. PATIENT SUMMARY: We studied adherence to active surveillance protocols for prostate cancer worldwide. We found that inclusion criteria were generally followed well, but adherence to repeat biopsy reduced with time. This should be considered when optimising future active surveillance protocols.
引用
- Kalapara AA, Verbeek JFM, Nieboer D, et al. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. Eur Urol Oncol. 2019. PMID: 31564531. doi:10.1016/j.euo.2019.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。